Ebola Therapeutic Study and Future Directions

Author(s): Da-Yong Lu*, Hong-Ying Wu, Nagendra S. Yarla, Ting-Ren Lu*, Bin Xu, Jian-Ding

Journal Name: Infectious Disorders - Drug Targets
Formerly Current Drug Targets - Infectious Disorders

Volume 19 , Issue 1 , 2019


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

The constant Ebola epidemic outbreaks in Africa arisen in waves of panic worldwide. There is a high mortality rate (30-70%) among the Ebola-infected people in virus- stricken areas. Despite these horrors, the medical capabilities against this deadly viral disease were provided by limited therapeutic agents/options. As a result, several patented agents, biotherapies or prophylactic/therapeutic vaccines need to be reviving into the global markets—including patents of small molecular chemicals, short sequences or oligomers of DNA/RNA, linkages of chemicals with bio-molecules, herbal medicine and so on. In addition, the possible mechanisms of action of these therapeutic options are underway. To promote Ebola biomedical study, the multiple characters of Ebola infections—its origin, pathologic progress, genomic changes, therapeutic context and economic considerations are outlined in this review. Finally, a great difference can be expected after these types of efforts.

Keywords: Ebola treatment, virus origin, viral pathogenesis, antiviral drugs, human genomes, traditional Chinese Medicine, drug development, drug patents.

[1]
Lu, D.Y. Important factors for controlling Ebola epidemics. Advanced Techniques in Biology & Medicine, 2014, 2, e103.
[2]
Labrijn, A.F.; Parren, P.W. Hitting Ebola, to the power of two. Science, 2016, 354(6310), 284-285.
[3]
Lu, D.Y.; Lu, T.R. Further suggestions for controlling Ebola epidemics. Int J Adv Biol Sci Engineering, 2015, 2, 57-59.
[4]
Lu, D.Y.; Lu, T.R.; Wu, H.Y.; Ding, J. Future perspectives for controlling Ebola epidemics. Metabolomics, 2015, 5, e135.
[5]
Gire, S.K.; Goba, A.; Andersen, K.G.; Sealfon, R.S.; Park, D.J.; Kanneh, L.; Jalloh, S.; Momoh, M.; Fullah, M.; Dudas, G.; Wohl, S.; Moses, L.M.; Yozwiak, N.L.; Winnicki, S.; Matranga, C.B.; Malboeuf, C.M.; Qu, J.; Gladden, A.D.; Schaffner, S.F.; Yang, X.; Jiang, P.P.; Nekoui, M.; Colubri, A.; Coomber, M.R.; Fonnie, M.; Moigboi, A.; Gbakie, M.; Kamara, F.K.; Tucker, V.; Konuwa, E.; Saffa, S.; Sellu, J.; Jalloh, A.A.; Kovoma, A.; Koninga, J.; Mustapha, I.; Kargbo, K.; Foday, M.; Yillah, M.; Kanneh, F.; Robert, W.; Massally, J.L.; Chapman, S.B.; Bochicchio, J.; Murphy, C.; Nusbaum, C.; Young, S.; Birren, B.W.; Grant, D.S.; Scheiffelin, J.S.; Lander, E.S.; Happi, C.; Gevao, S.M.; Gnirke, A.; Rambaut, A.; Garry, R.F.; Khan, S.H.; Sabeti, P.C. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science, 2014, 345(6202), 1369-1372.
[6]
Lu, D.Y.; Che, J.Y.; Lu, T.R.; Ding, J. Ebola origin and therapies. Metabolomics, 2015, 5, e138.
[7]
Lu, D.Y.; Wu, H.Y.; Lu, Y.; Lu, T.R. The origins of HIV. Adv. Pharmacoepidemiol. Drug Saf., 2015, 4, e136.
[8]
Lu, D.Y.; Wu, H.Y.; Yarla, N.S.; Lu, Y. The origins of HIV: A promising medical topic. HIV: Current Res., 2016, 1(2), 116.
[9]
Abbott, A.; Pearson, H. Fear of human pandemic grows as bird flu sweeps through Asia. Nature, 2004, 427(6974), 472-473.
[10]
Webster, R.; Hulse, D. Controlling avian flu at the source. Nature, 2005, 435(7041), 415-416.
[11]
Radriguez-Morales, A. Challenges for fish food-borne parasitic zoonotic diseases. Recent Patents Anti-Infect. Drug Disc., 2015, 10, 3-5.
[12]
Chowdhury, F.R.; Basher, A.; Amin, M.R.; Hassan, N.; Patwary, M.I. Rabies in South Asia: fighting for elimination. Recent Pat Antiinfect Drug Discov, 2015, 10(1), 30-34.
[13]
Goldberg, D.E.; Siliciano, R.F.; Jacobs, W.R. Jr Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell, 2012, 148(6), 1271-1283.
[14]
Pennisi, E. Microbiology. Contamination plagues some microbiome studies. Science, 2014, 346(6211), 801.
[15]
Schröder, A.R.W.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J.R.; Bushman, F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 2002, 110(4), 521-529.
[16]
Lu, D.Y.; Ding, J. Sequencing the whole genome of infected human cells obtained from diseased patients- proposed strategy for understanding and overcoming AIDS or other deadest virus-infected diseases. Med. Hypotheses, 2007, 68(4), 826-827.
[17]
Lu, D.Y.; Ding, J. AIDS and human genome studies, from a hypothesis to systematic approaches. Med. Hypotheses, 2007, 69(3), 695.
[18]
Lu, D.Y.; Lu, T.R.; Che, J.Y.; Wu, H.Y.; Xu, B. New perspectives of HIV/AIDS therapy study. Recent Pat Antiinfect Drug Discov, 2014, 9(2), 112-120.
[19]
Collins, F. Has the revolution arrived? Nature, 2010, 464(7289), 674-675.
[20]
Venter, J.C. Multiple personal genomes await. Nature, 2010, 464(7289), 676-677.
[21]
Lander, E.S. Initial impact of the sequencing of the human genome. Nature, 2011, 470(7333), 187-197.
[22]
Maher, B. Human genetics: Genomes on prescription. Nature, 2011, 478(7367), 22-24.
[23]
Lu, D.Y.; Lu, T.R. Mathematics or physics-majored students on the biomedical fields, insiders or outsiders. Metabolomics, 2015, 5(4), e142.
[24]
Lu, D.Y.; Wu, H.Y.; Lu, T.R.; Che, J.Y.; Lu, Y. Updating biomedical studies by recruiting more mathematics or physics-majored talents. Metabolomics, 2016, 6(2), e148.
[25]
Yoshida, H; Taoda, Y; Johns, BA; Kawasuji, TND Synthesis of carbamoyl pyridine HIV integrase inhibitors and intermediates. US2014094605 A1, 2014.
[26]
Oleman, PJ; Embrey, M; Hartingh, TJ; Powell, D; Raheem, IT; Chang, RK; Schreier, J; Sisko, J; Steele, T Walji, A Substituted naphthyridinedione derivatives as HIV integrase inhibitors., WO2014018449 A1, 2014.
[27]
Huang, W.; Petropoulos, C.J. Methods and compositions for determining virus susceptibility to integrase inhibitors. E, 2014, A1, 2678453.
[28]
Engelman, A. AIDS/HIV. A reversal of fortune in HIV-1 integration. Science, 2007, 316(5833), 1855-1857.
[29]
Cox, D.B.T.; Platt, R.J.; Zhang, F. Therapeutic genome editing: Prospects and challenges. Nat. Med., 2015, 21(2), 121-131.
[30]
Kupferschmidt, K. INFECTIOUS DISEASES. Surviving Ebola survival. Science, 2015, 348(6242), 1406-1407.
[31]
Cohen, J.; Kupferschmidt, K. Infectious Diseases. Ebola vaccine trials raise ethical issues. Science, 2014, 346(6207), 289-290.
[32]
Cohen, J.; Enserink, M. CLINICAL TRIALS. Ebola vaccines face daunting path to approval. Science, 2015, 349(6254), 1272-1273.
[33]
Lu, D.Y. Is vaccine always useful?, http://omicsonline.org/vaccines2011
[34]
Lu, D.Y.; Lu, T.R.; Wu, H.Y. Avian flu, pathogenesis and therapy. Antiinfect. Agents, 2012, 10, 124-129.
[35]
Cardile, A.P.; Mayers, D.L.; Bavari, S. Current status of chemically synthesized inhibitors of Ebola virus. Recent Pat Antiinfect Drug Discov, 2014, 9(2), 97-103.
[36]
Wadman, M. Vaccines on trial. Science, 2017, 356(6336), 370-373.
[37]
Kupferschmidt, K. The science of persuasion. Science, 2017, 356(6336), 366-369.
[38]
Lu, D.Y.; Wu, H.Y.; Lu, T.R.; Xu, B.; Ding, J. HIV vaccination, is breakthrough underway? Rev. Recent Clin. Trials, 2016, 11(2), 145-151.
[39]
Lu, D.Y.; Wu, H.Y.; Ding, J.; Sastry, N.; Lu, T.R. HIV vaccine for prevention and cure, a mission possible. Rev. Recent Clin. Trials, 2016, 11(4), 290-296.
[40]
Lu, D.Y.; Lu, T.R.; Lu, Y.; Sastry, N.; Wu, H.Y. Discover natural chemical drugs in modern medicines. Metabolomics, 2016, 6(3), 181.
[41]
Zhang, Z.J. (张仲景). Cold factors and treatments (伤寒论); People’s Medical and Public Health Publication: Beijing, PR China, 2005.
[42]
Rasmussen, A.L.; Okumura, A.; Ferris, M.T.; Green, R.; Feldmann, F.; Kelly, S.M.; Scott, D.P.; Safronetz, D.; Haddock, E.; LaCasse, R.; Thomas, M.J.; Sova, P.; Carter, V.S.; Weiss, J.M.; Miller, D.R.; Shaw, G.D.; Korth, M.J.; Heise, M.T.; Baric, R.S.; de Villena, F.P.; Feldmann, H.; Katze, M.G. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science, 2014, 346(6212), 987-991.
[43]
Pomerantz, R.J.; Horn, D.L. Twenty years of therapy for HIV-1 infection. Nat. Med., 2003, 9(7), 867-873.
[44]
Lu, D.Y.; Lu, T.R. High active antiretroviral therapy for HIV/AIDS, progresses and drawback. Adv. Pharmacoepidemiol. Drug Saf., 2012, 1, e115.
[45]
Lu, D.Y.; Lu, T.R.; Wu, H.Y.; Che, J.Y. Challenges for HIV/AIDS therapy. Adv. Pharmacoepidemiol. Drug Saf., 2013, 2, e120.
[46]
Lu, D.Y.; Lu, T.R.; Che, J.Y.; Ding, J.; Xu, B.; Wu, H.Y. Advances and shortcoming of HIV/AIDS therapy. Innovations in Pharmaceuticals and Pharmacotherapy., 2015, 3, 511-518.
[47]
Lu, D.Y.; Wu, H.Y.; Yarla, N.S.; Xu, B.; Ding, J.; Lu, T.R. HAART in HIV/AIDS treatments, future trends. Infect. Disord. Drug Targets, 2018, 18(1), 15-22.
[48]
Ali, I.; Saleem, K.; Uddin, R.; Haque, A.; El-Azzouny, A. Natural products: human friendly anti-cancer medications. Egypt Pharm J, 2010, 9, 133-179.
[49]
Prasad, S.; Tyagi, A.K. Traditional Medicine, the goldmine for modern drugs. Adv Tech Biol Med., 2015, 3(1), e108.
[50]
Lu, D.Y.; Lu, T.R.; Wu, H.Y. Zika therapy by traditional Chinese medicine, a new proposal. Adv Pharmacol Clinical Trial, 2016, 1(1), 103.
[51]
Liu, D.F.; Liu, Y.L.; Chen, H.; Zeng, W.L.; Wen, X.M.; Ye, Q.; Li, L.H.; Zhou, X.F. Evaluation on the curative effect and safety of Chinese traditional medicine in treatment of mild a/hH1N1 influenza in sichuan area. Mod. Prev. Med., 2011, 38(2), 338-343.
[52]
Zhou, Ho; Tao, LT; Xu, HC; Jiang, YG; Deng, YQ; Luo, Y Lu, CJ Discussion on Laws of Traditional Chinese Medical Treat-ment of H1N1 Influenza Based on Cohort Study. World Science and Technology/ Modernization of Traditional Chinese Medicine and Materia Medica., 2011, 13, 777-82.
[53]
Rumschlag-Booms, E.; Zhang, H.; Soejarto, D.D.; Fong, H.H.S.; Rong, L. Development of an antiviral screening protocol: One-stone-two-birds. J. Antivir. Antiretrovir., 2011, 3, 8-10.
[54]
Li, Y.H.; Yan, Q.B.; Yu, K.Z.; Tong, H.M.; Sun, Y. Study of the compound Chinese medicine against the anti-avian influenza virus. Zhongguo Nong Ye Ke Xue, 2008, 41, 1511-1518.
[55]
Lu, D.Y.; Lu, T.R.; Wu, H.Y. Treatment of influenza virus infections with Chinese medicine. Adv. Pharmacoepidemiol. Drug Saf., 2012, 1, e104.
[56]
Li, S.Z. (李时珍). Compendium of Materia Medica (本草纲目). Available at https://cn.hujiang.com/new/p488661/
[57]
Lu, D.Y.; Lu, T.R.; Wu, H.Y. Treatment of influenza virus infections with Chinese medicine. Adv. Pharmacoepidemiol. Drug Saf., 2012, 1, e104.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 1
Year: 2019
Published on: 04 February, 2019
Page: [17 - 29]
Pages: 13
DOI: 10.2174/1871526518666180813160348
Price: $65

Article Metrics

PDF: 58
HTML: 6